Profil wykonawcy
GILEAD SCIENCES,LDA
PT- Zamówienia
- 40
- Łączna wartość zamówień
- 22 059 751 €
- Kraje
- countries.BE, countries.PT
- Ostatnie zamówienie
- 14 lip 2026
- Wygasają w ciągu 12 miesięcy
- 0
Historia zamówień
| Data | Zamawiający | Tytuł | Kategoria | Wartość | Kraj | Wygasa | Źródło |
|---|---|---|---|---|---|---|---|
| 14.07.2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2023/0481 - SACITUZUMAB GOVITECANO [200 MG PÓ CONC SOL INJ FRS] | — | 164,2 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2023/0481 - SACITUZUMAB GOVITECANO [200 MG PÓ CONC SOL INJ FRS] | — | 684,2 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2023/0481 - SACITUZUMAB GOVITECANO [200 MG PÓ CONC SOL INJ FRS] | — | 136,8 tys. € | PT | — | Zobacz w TED ↗ |
| 09.07.2026 | Serviços de Saúde da Região Autónoma da Madeira, EPERAM (SESARAM; EPERAM) | Portugal – Various medicinal products – ANTIVIRICOS - 3 MESES | — | 370,4 tys. € | PT | — | Zobacz w TED ↗ |
| 08.04.2026 | Instituto Português de Oncologia do Porto Francisco Gentil, EPE | Portugal – Pharmaceutical products – Aquisição do medicamento Brexucabtagene autoleucel | — | 1,6 mln € | PT | — | Zobacz w TED ↗ |
| 03.04.2026 | Instituto Português de Oncologia do Porto Francisco Gentil, EPE | Portugal – Pharmaceutical products – Aquisiçao do Medicamento: Axicabtagene ciloleucel 0.4 - 2 x10e8 células Disp inj Fr 68 ml IV | — | 5,5 mln € | PT | — | Zobacz w TED ↗ |
| 16.12.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481 - AXICABTAGENE CILOLEUCEL [0.4 - 2 X10E8 CÉLULAS DISPERSÃO INJ SACO] | — | 273,1 tys. € | PT | — | Zobacz w TED ↗ |
| 16.12.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481 - AXICABTAGENE CILOLEUCEL [0.4 - 2 X10E8 CÉLULAS DISPERSÃO INJ SACO] | — | 273,1 tys. € | PT | — | Zobacz w TED ↗ |
| 16.12.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481 - AXICABTAGENE CILOLEUCEL [0.4 - 2 X10E8 CÉLULAS DISPERSÃO INJ SACO] | — | 273,1 tys. € | PT | — | Zobacz w TED ↗ |
| 02.12.2025 | Serviços de Saúde da Região Autónoma da Madeira, EPERAM (SESARAM; EPERAM) | Portugal – Various medicinal products – ANTIVIRICOS-BICTEGRAVIR+EMTRICITABINA+TENOFOVIR ALAFENAMIDA 2º SEMESTR | — | 430,0 tys. € | PT | — | Zobacz w TED ↗ |
| 14.10.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2023/0494 - SOFOSBUVIR + VELPATASVIR [400 + 100 MG; TRATAMENTO 12-24 SEMANAS] | — | 215,5 tys. € | PT | — | Zobacz w TED ↗ |
| 14.10.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - EMTRICITABINA + TENOFOVIR ALAFENAMIDA [200 + 25 MG COMP] | — | 474,0 tys. € | PT | — | Zobacz w TED ↗ |
| 14.10.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2023/0494 - SOFOSBUVIR + VELPATASVIR [400 + 100 MG; TRATAMENTO 12-24 SEMANAS] | — | 58,8 tys. € | PT | — | Zobacz w TED ↗ |
| 14.10.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - EMTRICITABINA + TENOFOVIR ALAFENAMIDA [200 + 25 MG COMP] | — | 95,1 tys. € | PT | — | Zobacz w TED ↗ |
| 16.09.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481 - AXICABTAGENE CILOLEUCEL [0.4 - 2 X10E8 CÉLULAS; DISPERSÃO INJ; SACO] | — | 296,3 tys. € | PT | — | Zobacz w TED ↗ |
| 16.09.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481 - AXICABTAGENE CILOLEUCEL [0.4 - 2 X10E8 CÉLULAS; DISPERSÃO INJ; SACO] | — | 296,3 tys. € | PT | — | Zobacz w TED ↗ |
| 16.09.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481 - AXICABTAGENE CILOLEUCEL [0.4 - 2 X10E8 CÉLULAS; DISPERSÃO INJ; SACO] | — | 296,3 tys. € | PT | — | Zobacz w TED ↗ |
| 16.09.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481 - AXICABTAGENE CILOLEUCEL [0.4 - 2 X10E8 CÉLULAS; DISPERSÃO INJ; SACO] | — | 296,3 tys. € | PT | — | Zobacz w TED ↗ |
| 16.09.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481 - AXICABTAGENE CILOLEUCEL [0.4 - 2 X10E8 CÉLULAS; DISPERSÃO INJ; SACO] | — | 296,3 tys. € | PT | — | Zobacz w TED ↗ |
| 19.08.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900- ELVITEGRAVIR + COBICISTATE + EMTRICITABINA + TENOFOVIR ALAFENAMIDA [150 + 150 + 200 +10 MG; CÁP/COMP] | — | 254,7 tys. € | PT | — | Zobacz w TED ↗ |
| 19.08.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - EMTRICITABINA + RILPIVIRINA + TENOFOVIR [200 MG + 25 MG + 245 MG; CÁP/COMP] | — | 50,5 tys. € | PT | — | Zobacz w TED ↗ |
| 19.08.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - EMTRICITABINA + RILPIVIRINA + TENOFOVIR [200 MG + 25 MG + 245 MG; CÁP/COMP] | — | 238,9 tys. € | PT | — | Zobacz w TED ↗ |
| 19.08.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900- ELVITEGRAVIR + COBICISTATE + EMTRICITABINA + TENOFOVIR ALAFENAMIDA [150 + 150 + 200 +10 MG; CÁP/COMP] | — | 50,9 tys. € | PT | — | Zobacz w TED ↗ |
| 12.08.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2023/0492 - REMDESIVIR [100 MG; PÓ CONC SOL INJ; FRS] | — | 51,8 tys. € | PT | — | Zobacz w TED ↗ |
| 12.08.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2023/0492 - REMDESIVIR [100 MG; PÓ CONC SOL INJ; FRS] | — | 258,8 tys. € | PT | — | Zobacz w TED ↗ |
| 15.07.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481-SACITUZUMAB GOVITECANO [200 MG; PÓ CONC SOL INJ; FRS] | — | 100,9 tys. € | PT | — | Zobacz w TED ↗ |
| 15.07.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481-SACITUZUMAB GOVITECANO [200 MG; PÓ CONC SOL INJ; FRS] | — | 95,9 tys. € | PT | — | Zobacz w TED ↗ |
| 15.07.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/0481-SACITUZUMAB GOVITECANO [200 MG; PÓ CONC SOL INJ; FRS | — | 479,3 tys. € | PT | — | Zobacz w TED ↗ |
| 08.07.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2023/0492 - ANFOTERICINA B LIPOSSÓMICA [50MG; IV; F/AMP] | — | 573,0 tys. € | PT | — | Zobacz w TED ↗ |
| 08.07.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2023/0492 - ANFOTERICINA B LIPOSSÓMICA [50MG; IV; F/AMP] | — | 120,6 tys. € | PT | — | Zobacz w TED ↗ |
| 17.06.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - EMTRICITABINA + RILPIVIRINA + TENOFOVIR ALAFENAMIDA [200 + 25 + 25 MG; COMP] | — | 1,0 mln € | PT | — | Zobacz w TED ↗ |
| 17.06.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - EMTRICITABINA + RILPIVIRINA + TENOFOVIR ALAFENAMIDA [200 + 25 + 25 MG; COMP] | — | 218,7 tys. € | PT | — | Zobacz w TED ↗ |
| 15.04.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900-Medicamentos antirretrovíricos para o tratamento da infeção por VIH (B712) | — | 760,2 tys. € | PT | — | Zobacz w TED ↗ |
| 15.04.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2024/0900-Medicamentos antirretrovíricos para o tratamento da infeção por VIH (B712) | — | 3,8 mln € | PT | — | Zobacz w TED ↗ |
| 03.12.2024 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/481-Medicamentos diversos (A53306) | — | 310,7 tys. € | PT | — | Zobacz w TED ↗ |
| 03.12.2024 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/481-Medicamentos diversos (A53306) | — | 310,7 tys. € | PT | — | Zobacz w TED ↗ |
| 03.12.2024 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2023/481-Medicamentos diversos (A53306) | — | 621,3 tys. € | PT | — | Zobacz w TED ↗ |
| 19.11.2024 | European Commission, DG HERA - European Health Emergency Preparedness and Response Authority | Belgium – Medicinal products for the respiratory system – Framework contract for the supply of Veklury | — | — | BE | — | Zobacz w TED ↗ |
| 12.11.2024 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – REMDESIVIR 100 MG INJ | — | 345,0 tys. € | PT | — | Zobacz w TED ↗ |
| 11.10.2024 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2023/492 - Medicamentos anti-infeciosos (R1091) | — | 345,0 tys. € | PT | — | Zobacz w TED ↗ |